Viking Therapeutics (VKTX) announced the initiation of the Vanquish Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
- Viking Therapeutics management to meet with B. Riley
- Viking Therapeutics Holds Annual Stockholders Meeting
- Viking Therapeutics put volume heavy and directionally bearish
- ARMOUR, BioCryst, Viking, Builders, Hims: Trending by Analysts